Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 66

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 66
---
 and percentage:

35

Three Months EndedMarch 31,Change20252024$%Direct program costs:Ovaprene (1)$1,495,727 $2,183,873 $(688,146)(32)%Sildenafil Cream, 3.6%211,389 460,107 (248,718)(54)%Other advanced clinical stage programs490,562 446,671 43,891 10 %Phase 1 and Phase 1-ready clinical stage programs (1)496,747 229,550 267,197 116 %Preclinical stage programs (1)1,098,738 1,371,708 (272,970)(20)%Other development programs— 12,794 (12,794)(100)%Contra R&D expenses (2)(2,618,373)(2,652,715)34,342 (1)%Total direct program costs1,174,790 2,051,988 (877,198)(43)%Indirect costs:Personnel-related (including stock compensation)1,492,248 1,482,597 9,651 1 %Outside services (including consulting)19,287 2,878 16,409 570 %Facilities-related (including depreciation)18,198 23,405 (5,207)(22)%Other indirect R&D costs41,250 51,916 (10,666)(21)%Contra R&D expenses(448,392)(259,264)(189,128)73 %Total indirect R&D costs1,122,591 1,301,532 (178,941)(14)%Total R&D expenses$2,297,381 $3,353,520 $(1,056,139)(31)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. 2.These contra R&D expenses were recognized as follows for the three months ended March 31, 2025 and 2024: (a) Ovaprene, $0.5 million, and $0, respectively; (b) other advanced clinical stage programs, $0.5 million and $0 respectively, (c) Phase